Colistin Dosage Administration in Patients with Impaired Renal Function

Dosing Recommendations Based on Renal Function

• A loading dose of 6-9 million IU should be administered to all patients regardless of renal function to rapidly achieve therapeutic levels 1, 2
• The loading dose is critical as colistin displays a relatively long half-life in relation to dosing intervals 1
• For patients with normal renal function, a maintenance dose of 2.5-5 mg/kg/day divided into 2-4 doses, or 9 million IU/day in 2-3 divided doses is recommended 1, 2
• For critically ill patients with severe sepsis/septic shock and normal renal function, 4.5 million IU every 12 hours is recommended 2
• Maintenance dose should be individually adjusted according to creatinine clearance for patients with mild renal impairment 2

Special Populations

Patients on Renal Replacement Therapy

• A dose of at least 9 million IU/day is recommended for patients on Continuous Renal Replacement Therapy (CRRT) 2, 3
• Polymyxin B may be a suitable alternative as it doesn't require dose adjustment during CRRT 1, 2
• For patients on Intermittent Hemodialysis, 2 million IU every 12 hours with a normal loading dose is recommended 2, 3
• Schedule dialysis toward the end of a colistin dosage interval for patients on Intermittent Hemodialysis 2

Administration Methods

• A 4-hour infusion is suggested to optimize pharmacokinetic/pharmacodynamic properties 1

Monitoring and Considerations

• Colistin is administered as colistimethate sodium (CMS), an inactive prodrug 1
• One million IU of colistin is equivalent to 80 mg of CMS 1
• Polymyxin B may be associated with lower incidence of renal failure compared to colistin 1

Colistin Dosing in Chronic Kidney Disease Patients

Maintenance Dosing Based on Creatinine Clearance

• For critically ill patients with normal renal function, the Infectious Diseases Society of America recommends an alternative dose of 4.5 million IU every 12 hours 4
• For patients with severe renal impairment, the National Kidney Foundation suggests a dose of 3.0-5.0 mg/kg IV every 24-36 hours 5

Critical Monitoring Requirements

• The American Society of Nephrology advises that renal function must be monitored closely during therapy, with checks at baseline and 2-3 times per week during treatment 5
• The European Renal Association notes that acute kidney injury is a major factor related to clinical failure and mortality, and close monitoring is essential 4

Special Populations: Renal Replacement Therapy

• For patients undergoing intermittent hemodialysis, the Clinical Infectious Diseases society recommends a dose of 3.0-5.0 mg/kg IV every 24 hours 5

Colistin Dosing Considerations in Renal Impairment

Introduction to Colistin Dosing

• The American College of Microbiology recommends administering a loading dose to rapidly achieve therapeutic levels, with a maintenance dose adjusted according to renal function 6

Critical Monitoring and Dosing Considerations

• The Infectious Diseases Society of America recommends monitoring renal function closely at baseline and 2-3 times per week during treatment due to the significant risk of acute kidney injury 6
• The National Kidney Foundation suggests that the recommended doses may be inadequate for pathogens with MIC ≥1 mg/L, particularly Pseudomonas species; consider combination therapy in these cases 6

Colistin Dosing Recommendations for Adults

Loading Dose

• All adult patients should receive an initial loading dose of 5 mg colistin base activity (CBA) per kilogram (≈ 9 million IU) intravenously, irrespective of renal function, to achieve therapeutic plasma concentrations promptly【7】.

Maintenance Dosing

• The routine maintenance dose is calculated with the formula 2.5 mg CBA × (1.5 × creatinine clearance + 30) mg administered intravenously every 12 hours; this dose must be adjusted according to the patient’s creatinine clearance using the same formula【7】.

Inhaled Adjunctive Therapy for Ventilator‑Associated Pneumonia (VAP)

• For VAP caused by carbapenem‑resistant organisms that are susceptible only to polymyxins, add inhaled colistin to the intravenous regimen as recommended by pneumonia‑specific guidelines【7】.

Dose Conversion

• 1 million IU of colistin methanesulfonate equals 33 mg of colistin base activity; this conversion is essential for accurate dosing and preparation【7】.

Renal Function Considerations

• Failure to adjust maintenance doses for renal function markedly increases the risk of nephrotoxicity; appropriate dose modification based on creatinine clearance is therefore critical【7】.

Colistin‑Related Acute Kidney Injury and Combination Therapy Considerations

Renal Toxicity and Clinical Impact

• Acute kidney injury that develops during or after colistin therapy is a key determinant of clinical failure and is associated with higher mortality rates in affected patients (observational data, 2022) 8.

Combination Therapy Evidence

• Current research provides only weak evidence regarding the efficacy of colistin‑based combination regimens, leaving the superiority of monotherapy versus combination therapy unresolved (low‑quality evidence, 2022) 8.
• If a combination approach is chosen, clinicians should select companion agents based on in‑vitro susceptibility, prioritizing those with the lowest minimum inhibitory concentration even when formal susceptibility is not established (expert opinion, weak evidence) 8.

Colistin Dosing Recommendations

Loading Dose (Universal)

Maintenance Dosing – General Population

Maintenance Dosing – Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT)

Intermittent Hemodialysis (IHD)

Dosing Conversions

Clinical Practice Recommendations

Colistin Use: Monitoring Renal Impact and Combination Therapy

Renal Safety and Clinical Outcomes

• Acute kidney injury that develops during colistin therapy is a major determinant of treatment failure and increased mortality. 11

Combination Therapy Recommendations

• For serious infections, colistin should be administered together with at least one additional antimicrobial (e.g., a carbapenem or another agent selected according to susceptibility testing) to improve clinical outcomes and reduce the selection of resistance. 11
• If no susceptible companion drug is available, colistin should be combined with a nonsusceptible agent that has the lowest minimum inhibitory concentration, to maximize the chance of therapeutic effect. 11